Kolesar Jill M
Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, USA.
Manag Care. 2008 Jul;17(7 Suppl 7):9-12; discussion 17-8.
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
通过基因表达谱对早期乳腺癌患者进行风险分类可大幅节省药物成本。经济分析表明，合理使用经临床验证的分子诊断方法具有节省成本和改善患者生活质量的潜力。
